Cover Page

Cite item


Based on the non-satisfactory results of the medicamental treatment of gastric cancer, the constant search is being carried out for new drugs with a sparing specter of side effects. Given the results of some investigations, it was assumed that Her-2-positive status of gastric cancer was associated with the aggressive disease course and unfavorable prognosis. According to publications data, clinical efficiency and safety of trastuzumab in combination with the first-line chemotherapy was assessed in patients with metastatic gastric cancer and Her-2 hypersecretion.

About the authors

L. M. Kogonia

M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)

Author for correspondence.
Russian Federation

A. G. Kornilova

M.F. Vladimirsky Moscow Regional Clinical and Research Institute (MONIKI)

Russian Federation


  1. Гарин А.М., Базин И.С. Справочное руководство по лекарственной терапии солидных опухолей. М., 2007.
  2. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и СНГ в 2006 г. // Вестн. РОНЦ им. Н.Н. Блохина РАМН. М., 2008. №9 (Прил. 1).
  3. Тюляндин С.А. Химиотерапия рака желудка // Практич. онкол. 2001. №3. С.44-51.
  4. Ajani J.A., Rodriguez W., Bodoky G. et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal ad-enocarcinoma study: the FLAGS trial // J. Clin. Oncol. 2010. V.28. P.1547-1553.
  5. Al-Batran S.E., Hartmann J.T., Probst S. et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluoro-uracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie // J. Clin. Oncol. 2008. V.26. P.1435-1442.
  6. Bang Y.J., Van Cutsem E., Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial // Lancet. 2011. V.376. P.687-697.
  7. Сomis R., Carter S. A review of chemotherapy in gastric cancer // Cancer. 1974. V.34. P.1576.
  8. Cunningham D., Starling N., Rao S. et al. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer // N. Engl. J. Med. 2008. V.358. P.36-46.
  9. Enzinger P., Burtness B., Hollis D. et al. CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer // J. Clin. Oncol. 2010. V.28. P.4006.
  10. Ferry D., Dutton S., Mansoor W. et al. Phase III multi-centre, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib) // Ann. Oncol. 2012. V.23 (Suppl. 9). P.20-31.
  11. Ford H., Marshall A., Wadsley J. et al. Cougar-02: A random-ized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma // J. Clin. Oncol. 2013. V.31. P.52-58.
  12. Fujimoto-Ouchi K., Mori K. Antitumor activity of trastuzum-ab in combination with chemotherapy in human gastric cancer xenograft models // Cancer Chemother. Pharmacol. 2007. V.59. P.795-805.
  13. Hudis C.A. Trastuzumab-mechanism of action and use in clinical practice // N. Engl. J. Med. 2007. V.357. P.39-51.
  14. Jemal A., Siegel R. Cancer statistics // J. Clin. Oncol. 2007. V.57. P.43-48.
  15. Kang J.H., Lee S.I., Lim D.H. et al. Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone // J. Clin. Oncol. 2012. V.30. P.1513-1518.
  16. Kang Y.K., Kang W.K., Shin D.B. et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomized phase III noninferiority trial // Ann. Oncol. 2009. V.20. P.666-673.
  17. Koizumi W., Narahara H., Hara T. et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial // Lancet. 2008. V.9. P.215-221.
  18. Lordick F., Bodoky G., Chung H. et al. Cetuximab in combination with capecitabine and cisplatin as first-line treatment in advanced gastric cancer: Randomized controlled phase III EXPAND study // Ann. Oncol. 2012. V.23 (Suppl. 9). P.3-8.
  19. Ohtsu A., Shah M.A., Van Cutsem E. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study // J. Clin. Oncol. 2012. V.29. P.3968-3976.
  20. Ross P., Nicolson M., Cunningham D. et al. Prospective ran-domized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer // J. Clin. Oncol. 2002. V.20. P.1996-2004.
  21. Shah M., Shibata S., Stoller R. et al. Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE) // J. Clin. Oncol. 2010. V.28. P.4014.
  22. Slamon D.J., Godolphin W. Studies of the HER2-n proto-oncogene in human breast and ovarian cancer // Science. 1989. V.244. P.707.
  23. Slamon D.J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer // N. Engl. J. Med. 2001. V.344. P.783-792.
  24. Tournigand C., Cervantes A., Figer A. et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer-a GERCOR study // J. Clin. Oncol. 2006. V.24. P.394-400.
  25. Ueda S., Hironaka S., Yasui H. et al. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial // J. Clin. Oncol. 2012. V.30. P.4002.
  26. Van Cutsem E., Moiseyenko V.M., Tjulandin S. et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group // J. Clin. Oncol. 2006. V.24. P.4991-4997.
  27. Waddell T., Chau I., Barbachano Y. et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3) // J. Clin. Oncol. 2012. V.30. P.40-48.
  28. Wagner A.D., Unverzagt S., Grothe W. et al. Chemotherapy for advanced gastric cancer // www.cohrane database syst. rev:CD004064.

Copyright (c) 2016 Kogonia L.M., Kornilova A.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies